Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Sei Investments Co.

Sei Investments Co. reduced its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 69.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 533,512 shares of the company’s stock after selling 1,187,954 shares during the quarter. Sei Investments Co. owned 0.05% of Teva Pharmaceutical Industries worth $9,390,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Capital Research Global Investors boosted its stake in Teva Pharmaceutical Industries by 13.8% in the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after acquiring an additional 9,260,426 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Teva Pharmaceutical Industries by 11.1% during the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock worth $2,218,958,000 after purchasing an additional 6,685,844 shares during the last quarter. FMR LLC raised its holdings in shares of Teva Pharmaceutical Industries by 16.7% during the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock worth $1,423,310,000 after purchasing an additional 6,115,853 shares during the last quarter. Northern Cross LLC raised its holdings in shares of Teva Pharmaceutical Industries by 14.0% during the second quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock worth $591,169,000 after purchasing an additional 2,184,172 shares during the last quarter. Finally, Nordea Investment Management AB increased its holdings in Teva Pharmaceutical Industries by 2.5% in the second quarter. Nordea Investment Management AB now owns 12,884,810 shares of the company’s stock valued at $428,033,000 after buying an additional 311,894 shares in the last quarter. 52.05% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts have weighed in on TEVA shares. TheStreet cut shares of Teva Pharmaceutical Industries from a “c-” rating to a “d+” rating in a report on Friday, August 25th. ValuEngine lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Evercore ISI set a $38.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Deutsche Bank reiterated a “buy” rating and issued a $28.00 target price (down from $43.00) on shares of Teva Pharmaceutical Industries in a report on Wednesday, August 9th. Finally, Cantor Fitzgerald set a $17.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Thursday, October 26th. Seven research analysts have rated the stock with a sell rating, seventeen have given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $21.65.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down $0.74 on Wednesday, hitting $14.32. 22,050,378 shares of the company traded hands, compared to its average volume of 15,674,337. The company has a debt-to-equity ratio of 1.20, a current ratio of 0.96 and a quick ratio of 0.66. Teva Pharmaceutical Industries Limited has a twelve month low of $10.85 and a twelve month high of $38.31. The firm has a market capitalization of $15,290.80, a PE ratio of 3.48 and a beta of 0.55.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be given a $0.085 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $0.34 annualized dividend and a dividend yield of 2.37%. Teva Pharmaceutical Industries’s dividend payout ratio is presently -12.10%.

TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Sei Investments Co.” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://ledgergazette.com/2017/12/07/sei-investments-co-sells-1187954-shares-of-teva-pharmaceutical-industries-limited-teva.html.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply